Drug Profile
ISIS EIF4ERx
Alternative Names: eIF-4E ASO; ISIS 183750; ISIS-EIF4ERx; LY 2275796; LY2275796 sodiumLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Eukaryotic initiation factor 4E inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Prostate cancer
Most Recent Events
- 12 Jul 2018 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Hungary, Poland, Russia, USA (IV)
- 12 Jul 2018 Discontinued - Phase-II for Prostate cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Russia, Puerto Rico, Hungary, Romania, Poland, USA (IV)
- 14 Aug 2015 No recent reports on development identified - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)